• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21894 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Effect of interventions to improve the quality of health services for ethnic minorities]
2015     The Netherlands Organisation for Health Research and Development (ZonMw) [Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients: the Dutch Convective Transport Study (CONTRAST)]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Effect of certification and accreditation of hospitals]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Effect of atrial natriuretic peptide, ANP, on the need for dialysis, when used as treatment or prevention of acute renal failure in intensive care]
2014     Norwegian Knowledge Centre for the Health Services (NOKC) [Effect of adapted interventions for primary child health care services]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Efavirenz, Emtricitabine and Tenofovir (Simplir®) in HIV infection – comparison with other brands in Argentina]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Efalizumab in treating psoriasis]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Edoxaban - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Edaravone in patients with amyotrophic lateral sclerosis]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Edaravone in patients with amyotrophic lateral sclerosis]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Eculizumab in the management of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Eculizumab for the treatment of paroxysmal nocturnal haemoglobinuria]
2011     Andalusian Health Technology Assessment Area (AETSA) [Eculizumab (Soliris®) Assessment of effectivity and safety of the drug and economic analysis of use in Paroxysmal Nocturnal Haemoglobinuria therapy]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) [eConsultation – a digital service centre]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Economic, organization and safety impact of drug robotic dispensing in Spanish hospitals]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of transanal endoscopic microsurgery]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Economic evaluation of the molecular diagnosis of the influenza virus]
2012     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Economic evaluation of the introduction of the HPV vaccine in Spain to prevent cervical cancer]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Economic evaluation of the first TNF-alpha inhibitor therapy in patients with rheumatoid arthritis]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Economic evaluation of single tooth replacement: dental implant vs. bridge]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of preimplantation genetic diagnosis (PGD) for screening]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of photoselective vaporization treatment for benign prostatic hyperplasia]
2010     Andalusian Health Technology Assessment Area (AETSA) [Economic evaluation of monitoring systems of ketones in blood for the diagnosis and prevention of ketoacidosis]
2011     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of laparoscopic versus conventional surgery in gastrointestinal surgery]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Economic evaluation of joint replacement surgery alongside a multi-centre randomized trial in elderly patients with displaced femoral neck fractures]
2013     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of drug eluting stents in the treatment of ischemic heart disease (update)]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic evaluation of drug eluting stents for high risk indications]
2015     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Economic evaluation of different strategies for screening for Chagas' disease in Spain]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [Economic evaluation of carotid artery stenting compared with carotid endarterectomy in patients with carotid artery stenosis]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Economic evaluation of a telemonitoring intervention from primary care in home care patients with cardiac insufficiency and/or chronic bronchial disorders: Cost-effectiveness analysis, TELBIL study]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Economic evaluation of a pneumococcal vaccination program in a pediatric population]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Economic dimensions of community nursing: A systematic literature review]
2008     Andalusian Health Technology Assessment Area (AETSA) [Economic assessment of mitral valve insufficiency treatment]
2008     Andalusian Health Technology Assessment Area (AETSA) [Economic assessment of mitral valve insufficiency treatment]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Economic assessment of genetic test in breast cancer treatment]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Economic assessment guide in the health sector]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Economic analysis of peripherally inserted central venous catheters (PICC), inserted by nursing staff, in cancer and hematological patients]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Early diagnostic and treatment of caries in the primary teeth- a health technology assessment]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection tools for emotional distress in adult people with cancer]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of vitamin B12 deficiency and other target diseases (homocystinuria, propionic acidaemia and methylmalonic acidaemia) in extended newborn screening (ENS)]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection of mucopolysaccharidosis and oligosaccharidosis by population screening in the newborn period. Systematic review]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of colorectal cancer in people with a family risk]
1994     Basque Office for Health Technology Assessment (OSTEBA) [Early detection of breast cancer in the Basque Country]
2010     The Swedish Council on Health Technology Assessment (SBU) [Early and focused ultrasonography in physical trauma]
2015     Basque Office for Health Technology Assessment (OSTEBA) [E-health systems to support cancer patients: proposal for the design of future assessment studies]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [E-health in caring for patients with atopic dermatitis. An economic evaluation comparing usual care with Internet-guided monitoring and self-management training by a nurse practitioner]
2014     The Swedish Council on Health Technology Assessment (SBU) [Dyslexia in children and adolescents – tests and interventions]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic stabilization with interspinous devices for spinal conditions]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging in pelvic floor dysfunction]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging for focal liver lesion assessment]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging for focal liver lesion assessment]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic fixation for spine degenerative diseases]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duvelisib (follicular lymphoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duvelisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Addendum to Commission A18-69]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Duration of antibiotic therapy: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (prurigo nodularis) – Addendum to Project A23-24]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in adolescents) - Addendum to Commission A19-75]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Duodeno-jejunal bypass liner (DJBL) for patients with obesity, with/without type 2 diabetes mellitus]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (Addendum to Commission A15-07)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dual target deep brain stimulation in refractory dystonia]
2008     Norwegian Knowledge Centre for the Health Services (NOKC) [Dual diagnoses – severe mental illness and substance use disorder. Part 2 – Effect of psychosocial interventions]
2007     Norwegian Knowledge Centre for the Health Services (NOKC) [Dual diagnoses - substance use disorder and severe mental illness. Part 1 - accuracy of screening- and diagnostic instruments]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Drugs in oncology: an overview of benefit and refund practices in Europe]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Drugs for smoking cessation]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Drug-eluting stents with rapamycin or paclitaxel versus conventional stents]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [Drug-eluting stents versus bare-metal stents in acute myocardial infarction]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Drug-eluting stents in coronary heart disease]
2014     The Swedish Council on Health Technology Assessment (SBU) [Drug-eluting stents in coronary arteries]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Drug-eluting balloon for the treatment of coronary stenosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilation catheter for the transurethral treatment of urethral strictures - Assessment according to §137h Social Code Book V - Third addendum to Commission H20-02]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilatation catheter for transurethral treatment of urethral strictures - Addendum to commission H20-02]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon catheter for the transurethral treatment of urethral strictures - Second addendum to commission H20-02]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug treatment of hypertension - update search (rapid report)]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Drug treatment of children with respiratory tract infections - a scoping review]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Drug treatment of ADHD (Attention Deficit/Hyperactivity Disorder) in adults in Germany]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]